Skip to Main content Skip to Navigation
Journal articles

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry

Abstract : Abstract The management of patients with atrial fibrillation (AF) has rapidly changed with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs) and changes in the use of rhythm control therapy. The prevention of thromboembolic events European Registry in Atrial Fibrillation Prolongation Registry (PREFER Prolongation) enrolled consecutive patients with AF on NOACs between 2014 and 2016 in a multicentre, prospective, observational study with one-year follow-up, focusing on the time of introduction of NOACs. Overall, 3783 patients were enrolled, with follow-up information available in 3223 (85%). Mean age was 72.2 ± 9.4 years, 40% were women, mean CHA 2 DS 2 VASc score was 3.4 ± 1.6, and 2587 (88.6%) had a CHA 2 DS 2 VASc score ≥ 2. Rivaroxaban was used in half of patients, and dabigatran and apixaban were used in about a quarter of patients each; edoxaban was not available for use in Europe at the time. Major cardiovascular event rate was low: serious events occurred in 74 patients (84 events, 2%), including 24 strokes (1%), 62 major bleeds (2%), of which 30 were life-threatening (1%) and 3 intracranial (0.1%), and 28 acute coronary syndromes (1%). Mortality was 2%. Antiarrhythmic drugs were used in about 50% of patients, catheter ablation in 5%. Adverse events were low in this contemporary European cohort of unselected AF patients treated with NOACs already at the time of their first introduction, despite high thromboembolic risk.
Document type :
Journal articles
Complete list of metadata

https://hal.univ-lorraine.fr/hal-03233120
Contributor : Jean-Marc Sellal <>
Submitted on : Sunday, May 23, 2021 - 8:39:59 PM
Last modification on : Saturday, May 29, 2021 - 3:15:00 AM

Links full text

Identifiers

Collections

Citation

Giulia Renda, Ladislav Pecen, Giuseppe Patti, Fabrizio Ricci, Dipak Kotecha, et al.. Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. Internal and Emergency Medicine, Springer, 2021, 16 (3), pp.591-599. ⟨10.1007/s11739-020-02442-9⟩. ⟨hal-03233120⟩

Share

Metrics

Record views

27